Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors
- Conditions
- Brain and Central Nervous System Tumors
- Registration Number
- NCT00003304
- Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients with recurrent oligodendroglial tumors following combination chemotherapy.
- Detailed Description
OBJECTIVES: I. Determine the response rate and duration of response in oligodendroglial tumors to temozolomide treatment in patients with progressive disease during or after procarbazine/lomustine/vincristine (PCV) chemotherapy. II. Determine the feasibility and toxicity of temozolomide chemotherapy following PVC chemotherapy in these patients.
OUTLINE: This is an open label, multicenter trial. Temozolomide is administered orally on days 1-5 of each 4-week course; treatment continues for a maximum of 12 courses. Patients are followed every 2 months for the first 6 months and then every 3 months thereafter.
PROJECTED ACCRUAL: A total of 16-29 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 29
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (37)
St. Elisabeth Ziekenhuis
🇳🇱Tilburg, Netherlands
Turku University Central Hospital
🇫🇮Turku, Finland
Institut Bergonie
🇫🇷Bordeaux, France
Hopital Louis Pasteur
🇫🇷Colmar, France
CHU de Nancy - Hopital Neurologique
🇫🇷Nancy, France
CRLCC Nantes - Atlantique
🇫🇷Nantes-Saint Herblain, France
Institut Gustave Roussy
🇫🇷Villejuif, France
CHU Pitie-Salpetriere
🇫🇷Paris, France
Universitaetsklinikum Benjamin Franklin
🇩🇪Berlin, Germany
Azienda Ospedaliera di Padova
🇮🇹Padova (Padua), Italy
Universita Degli Studi di Torino
🇮🇹Torino, Italy
Academisch Ziekenhuis Maastricht
🇳🇱Maastricht, Netherlands
St. Radboud University Hospital
🇳🇱Nijmegen, Netherlands
Rotterdam Cancer Institute
🇳🇱Rotterdam, Netherlands
Kaiser Franz Josef Hospital
🇦🇹Vienna (Wien), Austria
Helsinki University Central Hospital
🇫🇮Helsinki, Finland
Centre Regional Francois Baclesse
🇫🇷Caen, France
CHU de la Timone
🇫🇷Marseille, France
Hopital Universitaire Erasme
🇧🇪Brussels, Belgium
Hopital Pasteur
🇫🇷Nice, France
Centre Hospitalier Universitaire de Bicetre
🇫🇷Le Kremlin Bicetre, France
National Institute of Neurosurgery
ðŸ‡ðŸ‡ºBudapest, Hungary
Universitaetsklinikum Tuebingen
🇩🇪Tuebingen, Germany
Centre Leon Berard
🇫🇷Lyon, France
Centre Antoine Lacassagne
🇫🇷Nice, France
C.H.R. de Nimes - Hopital Caremeau
🇫🇷Nimes, France
Western General Hospital
🇬🇧Edinburgh, Scotland, United Kingdom
Rigshospitalet
🇩🇰Copenhagen, Denmark
Neurologische Klinik der Henriettenstiftung
🇩🇪Hannover, Germany
Academisch Ziekenhuis der Vrije Universiteit
🇳🇱Amsterdam, Netherlands
Antoni van Leeuwenhoekhuis
🇳🇱Amsterdam, Netherlands
Academisch Ziekenhuis Groningen
🇳🇱Groningen, Netherlands
Dr. Bernard Verbeeten Instituut
🇳🇱Tilburg, Netherlands
Academisch Ziekenhuis Utrecht
🇳🇱Utrecht, Netherlands
Instituto Portugues de Oncologia de Francisco Gentil
🇵🇹Lisbon, Portugal
Umea Universitet
🇸🇪Umea, Sweden
Beatson Oncology Centre
🇬🇧Glasgow, Scotland, United Kingdom